Secondary Logo

Journal Logo

NCPD Connection


Moving toward eradication

Author Information
doi: 10.1097/01.NPR.0000831000.08670.bc
  • Free

INSTRUCTIONS Measles: Moving toward eradication


  • Read the article. The test for this CE activity is to be taken online at Tests can no longer be mailed or faxed.
  • You'll need to create (it's free!) and log in to your personal CE Planner account before taking online tests. Your planner will keep track of all your Lippincott Professional Development online CE activities for you.
  • There's only one correct answer for each question. A passing score for this test is 7 correct answers. If you pass, you can print your certificate of earned contact hours and access the answer key. If you fail, you have the option of taking the test again at no additional cost.
  • For questions, contact Lippincott Professional Development: 1-800-787-8985.
  • Registration deadline is March 7, 2025.


Lippincott Professional Development will award 2.0 contact hours and 1.0 pharmacology consult hour for this continuing nursing education activity.

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 2.0 contact hours. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia, Georgia, West Virginia, New Mexico, South Carolina, and Florida, CE Broker #50-1223. Your certificate is valid in all states.

Payment: The registration fee for this test is $21.95.

Measles: Moving toward eradication

Learning Outcomes: Seventy-five percent of participants will be able to demonstrate an increase in knowledge regarding moving toward measles eradication by achieving a posttest score of 70% or greater.

Learning Objectives: After reading the article and completing the posttest, the participant will be able to: 1. Describe the morbidity and mortality of measles disease and its complications. 2. Summarize the issues related to vaccination rates and vaccine hesitancy with regard to measles. 3. Discern strategies for identifying and treating measles disease and measles exposures along with primary prevention strategies.


Case-Based Assessment: Placing yourself in the role of the NP, use the scenario below to apply knowledge and skills learned in the attached article.

Questions #1 - #10 are based on the below Case Scenario.

Case Scenario: You practice as an NP in a primary care practice. You receive information from a local school district that there is concern about a measles outbreak occurring in their schools.

  1. Which of the following factors is likely to be associated with a local measles outbreak?
    1. students gathering in school for extended periods of time
    2. late summer development of upper respiratory tract symptoms
    3. routine vaccination rates beginning to improve within the community
  2. The measles-mumps-rubella (MMR) vaccine succeeded in which of the following?
    1. eliminating deaths in those with subacute sclerosing panencephalitis
    2. increasing the frequency of measles in patients who are immunocompromised
    3. reducing childhood morbidity and mortality from measles disease
  3. Information to share with parents and local school officials includes stating that complications can arise in children with measles
    1. less than 10% of the time, and most often are very mild, including cough.
    2. approximately 30% of the time, and can include pneumonia and blindness.
    3. more than 50% of the time, with subacute sclerosing panencephalitis occurring frequently.
  4. Which of the following factors would not help to explain the measles outbreak in the local school district?
    1. There are underimmunized individuals living in the community.
    2. A 30% increase in vaccination rates occurred at the school district since the pandemic.
    3. There has been an influx of travelers with unknown vaccination status.
  5. An essential priority to reduce the risk for future measles outbreaks includes
    1. development of campaigns for “catch-up” vaccinations.
    2. changing the parameters of what constitutes herd immunity.
    3. publication of evidence about unsafe adjuvants and preservatives.
  6. In counseling parents in your community regarding MMR immunizations, it is essential to
    1. stress attendance at well-child visits to maintain up-to-date immunizations.
    2. avoid discussion of vaccination myths to reduce parental discomfort about the topic.
    3. encourage spacing of multiple vaccinations to enhance each child's neurodevelopment.
  7. Parents of several children pulled their children from school when they developed a rash suspicious for measles. School officials ask why the disease has still spread. What is the best response?
    1. Children should have been started on prophylactic antibiotics to stop the spread of disease.
    2. The virus has a 20- to 30-day incubation period and is contagious weeks before the rash appears.
    3. Children are considered infectious starting about 4 days prior to rash onset and until 4 days following rash appearance.
  8. A child presents to your clinic with Koplik spots, cough, conjunctivitis, and coryza. Which phase of measles does this most likely represent?
    1. recovery
    2. prodromal
    3. incubation
  9. You are rounding on several hospitalized children who have measles. What treatment should you prescribe for all of these patients?
    1. antibiotics
    2. antivirals
    3. vitamin A
  10. An 8-month-old child in your practice had a confirmed exposure to a patient with measles about 36 hours ago. What is the correct treatment?
    1. Give immunoglobulin now along with MMR, then repeat MMR per current immunization guidelines.
    2. Administer MMR now, then again at 12-15 months of age, and then at age 4-6 years.
    3. Give MMR now, skip the dose at 12-15 months of age, and then give MMR again at age 4-6 years.
Wolters Kluwer Health, Inc. All rights reserved.